A detailed history of Black Rock Inc. transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 1,418,855 shares of TYRA stock, worth $19.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,418,855
Previous 1,044,225 35.88%
Holding current value
$19.9 Million
Previous $17.1 Million 32.48%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$14.45 - $20.22 $5.41 Million - $7.58 Million
374,630 Added 35.88%
1,418,855 $22.7 Million
Q1 2024

May 10, 2024

BUY
$11.61 - $20.0 $919,407 - $1.58 Million
79,191 Added 8.21%
1,044,225 $17.1 Million
Q4 2023

Feb 13, 2024

BUY
$11.01 - $14.95 $755,087 - $1.03 Million
68,582 Added 7.65%
965,034 $13.4 Million
Q3 2023

Nov 13, 2023

BUY
$13.15 - $16.08 $73,903 - $90,369
5,620 Added 0.63%
896,452 $12.3 Million
Q2 2023

Aug 11, 2023

BUY
$11.99 - $17.51 $2.69 Million - $3.92 Million
223,947 Added 33.58%
890,832 $15.2 Million
Q1 2023

May 12, 2023

BUY
$6.85 - $16.22 $80,788 - $191,298
11,794 Added 1.8%
666,885 $10.7 Million
Q4 2022

Feb 13, 2023

BUY
$5.68 - $8.81 $187,400 - $290,668
32,993 Added 5.3%
655,091 $4.98 Million
Q3 2022

Nov 14, 2022

SELL
$6.61 - $12.42 $57,883 - $108,761
-8,757 Reduced 1.39%
622,098 $5.47 Million
Q2 2022

Aug 12, 2022

BUY
$5.26 - $11.19 $250,475 - $532,856
47,619 Added 8.16%
630,855 $4.51 Million
Q1 2022

May 12, 2022

SELL
$10.03 - $14.09 $53,459 - $75,099
-5,330 Reduced 0.91%
583,236 $6.24 Million
Q4 2021

Feb 10, 2022

BUY
$12.23 - $31.35 $7.2 Million - $18.5 Million
588,566 New
588,566 $8.28 Million

Others Institutions Holding TYRA

About Tyra Biosciences, Inc.


  • Ticker TYRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,973,600
  • Market Cap $588M
  • Description
  • Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...
More about TYRA
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.